Critical Illness Endocrine Response: Two Phases Requiring Different Treatment Approaches | Research

The takeaway

The neuroendocrine response to critical illness has two distinct phases — an acute beneficial activation followed by a chronic harmful suppression — and treatment must match the phase for optimal outcomes.

Phase matters
Augmenting hormones in acute illness can be harmful, but restoring them in chronic suppression can be life-saving — timing determines whether treatment helps or hurts

What the researchers found

The neuroendocrine response to critical illness is biphasic (acute activation → chronic suppression), and therapeutic intervention must be phase-appropriate: GH secretagogues/TRH benefit the chronic phase but acute-phase augmentation may be harmful.

Why it matters

Timing is everything in ICU endocrine therapy. This review explains why the same therapy (GH augmentation) can save lives in chronic illness but kill patients in acute illness.

How the study worked

Clinical review integrating neuroendocrine profiling data from critically ill patients with clinical trial outcomes, including the negative GH replacement trial and positive GH secretagogue studies.

What this study cannot tell us

Review based on available clinical data through 2001. Optimal timing of GH secretagogue therapy not precisely defined.

How to read the evidence

Moderate evidence from a clinical review integrating biphasic physiology with trial outcomes, providing a coherent therapeutic framework.

When this study was published

Published in 2001 by the Leuven group. The biphasic model has been refined and remains the dominant framework for understanding ICU neuroendocrine dysfunction.

The bigger picture

ICU medicine increasingly recognizes that critical illness is not a static state — it evolves through distinct phases requiring different treatments. Endocrine therapy must be matched to the disease phase for safety.

Questions still open

How do clinicians determine which phase a patient is in?
Could biomarkers guide phase-appropriate endocrine therapy?
Should all prolonged ICU patients receive GH secretagogue assessment?

Common questions

Why does treatment timing matter in the ICU?

Early in critical illness, the body's hormone surge is protective. Boosting hormones further can be dangerous (this is what the failed GH trial showed). But weeks later, hormones become suppressed, and restoring them with GH secretagogues can help recovery.

How do doctors know which phase a patient is in?

Generally, the acute phase lasts hours to days, and the chronic suppression phase begins after several days in the ICU. Hormone levels and clinical trajectory help determine the appropriate timing for intervention.

Read the original research

The neuroendocrine response to stress is a dynamic process.

Best practice & research. Clinical endocrinology & metabolism, 15(4), 405-19

View on PubMed ↗

Citation

Van den Berghe, G. (2001). The neuroendocrine response to stress is a dynamic process.. Best practice & research. Clinical endocrinology & metabolism, 15(4), 405-19.